These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 10674022)

  • 21. Mechanisms of resistance of human small cell lung cancer lines selected in VP-16 and cisplatin.
    Jain N; Lam YM; Pym J; Campling BG
    Cancer; 1996 May; 77(9):1797-808. PubMed ID: 8646677
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Differential patterns of anti-tumour drug responses and mechanisms of resistance in a series of independently-derived VP-16-resistant human tumour cell lines.
    Lock RB; Hill BT
    Int J Cancer; 1988 Sep; 42(3):373-81. PubMed ID: 3417366
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Human melanoma cell lines selected in vitro displaying various levels of drug resistance against cisplatin, fotemustine, vindesine or etoposide: modulation of proto-oncogene expression.
    Kern MA; Helmbach H; Artuc M; Karmann D; Jurgovsky K; Schadendorf D
    Anticancer Res; 1997; 17(6D):4359-70. PubMed ID: 9494534
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Demonstration of differential gene expression between sensitive and resistant ovarian tumor cells by fluorescence differential display-PCR analysis.
    Li L; Luan Y; Li X; Tang B; Zhang W; Li D; Zhao J; Wang G; Ding H; Reed E; Li QQ
    Oncol Rep; 2005 May; 13(5):793-9. PubMed ID: 15809740
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ascorbic acid increases drug accumulation and reverses vincristine resistance of human non-small-cell lung-cancer cells.
    Chiang CD; Song EJ; Yang VC; Chao CC
    Biochem J; 1994 Aug; 301 ( Pt 3)(Pt 3):759-64. PubMed ID: 7914401
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anti-tumour activities of a new benzo[c]phenanthridine agent, 2,3-(methylenedioxy)-5-methyl-7-hydroxy-8-methoxybenzo[c]phena nthridini um hydrogensulphate dihydrate (NK109), against several drug-resistant human tumour cell lines.
    Kanzawa F; Nishio K; Ishida T; Fukuda M; Kurokawa H; Fukumoto H; Nomoto Y; Fukuoka K; Bojanowski K; Saijo N
    Br J Cancer; 1997; 76(5):571-81. PubMed ID: 9303354
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Development and characterization of cisplatin-resistant human testicular and bladder tumour cell lines.
    Walker MC; Povey S; Parrington JM; Riddle PN; Knuechel R; Masters JR
    Eur J Cancer; 1990; 26(6):742-7. PubMed ID: 2144165
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lack of a role for MRP1 in platinum drug resistance in human ovarian cancer cell lines.
    Sharp SY; Smith V; Hobbs S; Kelland LR
    Br J Cancer; 1998 Jul; 78(2):175-80. PubMed ID: 9683290
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hypoxia influences stem cell-like properties in multidrug resistant K562 leukemic cells.
    Cui XY; Skretting G; Jing Y; Sun H; Sandset PM; Sun L
    Blood Cells Mol Dis; 2013 Oct; 51(3):177-84. PubMed ID: 23725749
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Development of rational in vitro models for drug resistance in breast cancer and modulation of MDR by selected compounds.
    Kars MD; Iseri OD; Gündüz U; Ural AU; Arpaci F; Molnár J
    Anticancer Res; 2006; 26(6B):4559-68. PubMed ID: 17201178
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Titanocendichloride activity in cisplatin and doxorubicin-resistant human ovarian carcinoma cell lines.
    Harstrick A; Schmoll HJ; Sass G; Poliwoda H; Rustum Y
    Eur J Cancer; 1993; 29A(7):1000-2. PubMed ID: 8499130
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Gene expression profiling of drug-resistant small cell lung cancer cells by combining microRNA and cDNA expression analysis.
    Guo L; Liu Y; Bai Y; Sun Y; Xiao F; Guo Y
    Eur J Cancer; 2010 Jun; 46(9):1692-702. PubMed ID: 20371173
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Isolation and molecular cloning of human sorcin a calcium-binding protein in vincristine-resistant HOB1 lymphoma cells.
    Wang SL; Tam MF; Ho YS; Pai SH; Kao MC
    Biochim Biophys Acta; 1995 Feb; 1260(3):285-93. PubMed ID: 7873602
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Binding of doxorubicin to Sorcin impairs cell death and increases drug resistance in cancer cells.
    Genovese I; Fiorillo A; Ilari A; Masciarelli S; Fazi F; Colotti G
    Cell Death Dis; 2017 Jul; 8(7):e2950. PubMed ID: 28726784
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Relationships between resistance to cisplatin and antifolates in sensitive and resistant tumour cell lines.
    Kelland LR; Kimbell R; Hardcastle A; Aherne GW; Jackman AL
    Eur J Cancer; 1995 Jun; 31A(6):981-6. PubMed ID: 7646933
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Enhanced in vitro invasiveness and drug resistance with altered gene expression patterns in a human lung carcinoma cell line after pulse selection with anticancer drugs.
    Liang Y; O'Driscoll L; McDonnell S; Doolan P; Oglesby I; Duffy K; O'Connor R; Clynes M
    Int J Cancer; 2004 Sep; 111(4):484-93. PubMed ID: 15239124
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identification of the human prostatic carcinoma oncogene PTI-1 by rapid expression cloning and differential RNA display.
    Shen R; Su ZZ; Olsson CA; Fisher PB
    Proc Natl Acad Sci U S A; 1995 Jul; 92(15):6778-82. PubMed ID: 7542776
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In vitro evaluation of antimicrotubule agents in human small-cell lung cancer cell lines.
    Ikubo S; Takigawa N; Ueoka H; Kiura K; Tabata M; Shibayama T; Chikamori M; Aoe K; Matsushita A; Harada M
    Anticancer Res; 1999; 19(5B):3985-8. PubMed ID: 10628341
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cross-resistance to cis-diamminedichloroplatinum(II) of a multidrug-resistant lymphoma cell line associated with decreased drug accumulation and enhanced DNA repair.
    Chao CC
    Eur J Pharmacol; 1996 Jun; 305(1-3):213-22. PubMed ID: 8813556
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cross-resistance to tumour promoters in human cancer cell lines resistant to adriamycin or cisplatin.
    Nishio K; Sugimoto Y; Nakagawa K; Niimi S; Fujiwara Y; Bungo M; Kasahara K; Fujiki H; Saijo N
    Br J Cancer; 1990 Sep; 62(3):415-9. PubMed ID: 2206949
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.